Q32 Bio is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. 

Biotechnology

Q32 Bio

Q32 Bio's headquarters in Cambridge, MA, United States

Jodie Morrison

Saul W. Fink

Saul Fink

Lee Kalowski

Adrien Sipos

David Appugliese

Shelia Violette

Bill Lundberg

Mark Iwicki

Michael Holers

Diyong Xu

Brian Kotzin

David Grayzel

Isaac Manke

John P. Atkinson

Kathy LaPorte

Arthur Tzianabos

Mary Thistle

The Finance & Strategic Planning team at Q32 Bio plays a crucial role in ensuring the company’s financial health and strategic direction. This team is responsible for budgeting, financial analysis, and forecasting, while also collaborating with other departments to align financial strategies with the company's goals in developing innovative therapies for autoimmune and inflammatory diseases. Their insights and planning efforts enable informed decision-making that supports the company's growth and operational efficiency.

Finance & Strategic Planning

The Scientific Research & Development team at Q32 Bio is dedicated to advancing innovative therapies that target key regulators of the immune system. Comprising experts in pharmacology, protein science, and translational biology, the team collaborates to design and execute preclinical studies, develop cutting-edge biologics, and navigate regulatory processes. Their goal is to translate scientific discoveries into effective treatments for autoimmune and inflammatory diseases.

Scientific Research & Development

The Clinical Operations team at Q32 Bio is responsible for the planning, implementation, and management of clinical trials that evaluate the safety and efficacy of innovative immunotherapies. This team ensures compliance with regulatory standards, oversees study protocols, coordinates with clinical sites, and collects and analyzes trial data to support the advancement of therapies aimed at re-balancing the immune system in patients with severe autoimmune and inflammatory diseases.

Clinical Operations

The Leadership Team at Q32 Bio drives the strategic direction and operational execution of the company's initiatives in developing innovative therapies for autoimmune and inflammatory diseases. Comprising key executives in research, medical leadership, corporate strategy, and human resources, the team collaborates to align organizational efforts, ensure regulatory compliance, and foster a culture of scientific excellence and employee engagement. Their collective expertise is crucial in navigating the complexities of biotech development and advancing the company’s mission to rebalance the immune system.

Leadership Team

The Quality Assurance & Regulatory Affairs team at Q32 Bio ensures that all processes and products meet stringent regulatory standards and quality expectations. They oversee compliance with industry regulations, implement quality management systems, and facilitate interactions with regulatory agencies to support the development and approval of innovative therapies for autoimmune and inflammatory diseases.

Quality Assurance & Regulatory Affairs

This department manages financial transactions, reporting, and auditing for the organization.

Q32 Bio

Org chart

Board & advisors

Teams

Finance & Strategic Planning

Scientific Research & Development

Clinical Operations

Leadership Team

Quality Assurance & Regulatory Affairs

Accounting Services

Offices

Q32 Bio

Org chart

Board & advisors

Teams

Finance & Strategic Planning

Scientific Research & Development

Clinical Operations

Leadership Team

Quality Assurance & Regulatory Affairs

Accounting Services

Offices

Related companies